Streetbeat News

Earnings

JAGX

Jaguar Health (NASDAQ:JAGX) reported a decrease in Q4 EPS to $0.42 from $0.57 YoY, but sales surged to $2.30B, significantly beating the $2.61M estimate and marking a 70.45K percent increase from last year's $3.26M.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:46 pm

ONDS

Ondas Holdings (NASDAQ:ONDS) reported Q4 losses of $(0.17) per share, missing the $(0.14) estimate, but saw sales of $4.96M, beating the $4.27M estimate. This represents a significant improvement over the previous year, with losses decreasing by 61.36% and sales increasing by 935.89%.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:44 pm

STSS

Sharps Technology (NASDAQ:STSS) reported a Q4 EPS loss of $(0.17), a 112.5% increase in losses compared to $(0.08) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:41 pm

SGML

Sigma Lithium announces a final investment decision to double its production capacity to 520,000 tonnes/year with a $100M investment in Phase 2 of its Industrial Greentech Plant. The expansion aims to power 1.8 million EVs and is expected to be completed in 10 months, with construction starting in 4Q24. The company plans to finance the expansion with existing cash and future cash flow from lithium concentrate shipments. Sigma Lithium ended its first production year with positive cash adjusted EBITDA and operating profit, despite a decline in lithium prices.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:39 pm

HTCR

HeartCore Enterprises, Inc. (NASDAQ:HTCR) announced its first dividend payment of $0.02 per share, totaling $417,283. The decision follows a positive financial review and a recent cash influx from a Go IPO client warrant sale. The record date is April 26, 2024, with payment on May 3, 2024. Future dividends may be issued quarterly based on financial results. CEO Sumitaka Kanno Yamamoto highlighted the company's strong financial health and the Go IPO pipeline as key growth drivers.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:32 pm

GES

Guess? Inc (NYSE:GES) shares surged in premarket trading after announcing a new $200 million share repurchase program and a convertible bond exchange transaction. The company has repurchased 326,429 shares for $10.3 million and entered into an agreement to exchange convertible senior notes due 2024 for new notes due 2028. This follows a strong Q4 earnings report that exceeded analyst expectations.

Portfolio Pulse from Shivani Kumaresan

April 01, 2024 | 12:31 pm

NXGL

NexGel (NASDAQ:NXGL) reported Q4 2023 GAAP EPS of $(0.20), missing the $(0.11) estimate, and sales of $1.082M, below the $1.380M estimate. Despite the miss, sales increased 106.49% from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:24 pm

VISL

Vislink Technologies (NASDAQ:VISL) reported a Q4 EPS loss of $(0.99), an improvement from a $(2.40) loss YoY. Sales increased to $8.10M from $7.38M YoY.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:23 pm

ESCA

Escalade Inc (NASDAQ:ESCA) reported a Q4 FY23 sales decline of 9.2% YOY to $65.51 million, missing estimates. Despite softer consumer demand, improved demand in basketball and indoor games, and operational efficiencies led to a gross margin increase to 24.3% and an operating income increase to $5.0 million. The company announced a quarterly dividend of $0.15 per share, payable on April 22, 2024. CEO Walter P. Glazer, Jr. anticipates margin improvements in 2024 due to lower inventory costs and operational improvements. ESCA shares closed up 4.25% at $13.75.

Portfolio Pulse from Shivani Kumaresan

April 01, 2024 | 12:16 pm

IRON

Disc Medicine, Inc. (NASDAQ:IRON) announced positive topline results from the Phase 2 AURORA study of bitopertin in Erythropoietic Protoporphyria (EPP) patients. The study met its primary endpoint, showing significant reductions in protoporphyrin IX (PPIX) levels and improvements in light tolerance and phototoxic reactions with pain, particularly at the 60 mg dose. However, some secondary endpoints did not achieve statistical significance due to a strong placebo response. The company plans further analysis and discussions with regulators to define future study endpoints.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:13 pm